{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:08:44Z","timestamp":1793200124164,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01623-0","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:58:19Z","timestamp":1742374699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of the effectiveness and safety of lenvatinib\/bevacizumab combined with PD-1\/PD-L1 inhibitors and GEMOX in the first-line treatment of advanced biliary tract carcinoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Lu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjie","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"1623_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41575-022-00587-w","volume":"19","author":"E Zhuravleva","year":"2022","unstructured":"Zhuravleva E, O\u2019Rourke CJ, Andersen JB. Mutational signatures and processes in hepatobiliary cancers. Nat Rev Gastroenterol Hepatol. 2022;19:367\u201382.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1623_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1623_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet"},{"key":"1623_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. oxaliplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"1623_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/cam4.299","volume":"3","author":"F Fiteni","year":"2014","unstructured":"Fiteni F, Nguyen T, Vernerey D, et al. oxaliplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med. 2014;3:1502\u201311.","journal-title":"Cancer Med"},{"key":"1623_CR6","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147:2190\u20138.","journal-title":"Int J Cancer"},{"key":"1623_CR7","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/ijc.33751","volume":"149","author":"X Chen","year":"2021","unstructured":"Chen X, Qin S, Gu S, et al. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: a multicenter, phase 2 trial. Int J Cancer. 2021;149:1944\u201354.","journal-title":"Int J Cancer"},{"key":"1623_CR8","first-page":"638747","volume":"2014","author":"T Kimura","year":"2014","unstructured":"Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.","journal-title":"J Thyroid Res"},{"key":"1623_CR9","doi-asserted-by":"publisher","first-page":"110797","DOI":"10.1016\/j.biopha.2020.110797","volume":"132","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jiang M, Zhu J, Qu J, Qin K, Zhao D, Wang L, Dong L, Zhang X. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomed Pharmacother. 2020;132:110797.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1623_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/hbsn-20-338","volume":"9","author":"J Lin","year":"2020","unstructured":"Lin J, Yang X, Long J, Zhao S, Mao J, Wang D, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobil Surg Nutr. 2020;9(4):414\u201324.","journal-title":"Hepatobil Surg Nutr"},{"key":"1623_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discovery. 2004;3:391\u2013400.","journal-title":"Nat Rev Drug Discovery"},{"issue":"13","key":"1623_CR12","doi-asserted-by":"publisher","first-page":"175883592110365","DOI":"10.1177\/17588359211036544","volume":"31","author":"SP Hack","year":"2021","unstructured":"Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol. 2021;31(13):17588359211036544.","journal-title":"Ther Adv Med Oncol"},{"key":"1623_CR13","doi-asserted-by":"publisher","first-page":"751391","DOI":"10.3389\/fonc.2021.751391","volume":"11","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Liu X, Wei S, Zhang L, Tian Y, Gao Z, et al. Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label. Phase II Stud Front Oncol. 2021;11:751391.","journal-title":"Phase II Stud Front Oncol"},{"key":"1623_CR14","doi-asserted-by":"publisher","first-page":"S376","DOI":"10.1016\/j.annonc.2021.08.328","volume":"32","author":"N Chiang","year":"2021","unstructured":"Chiang N, Bai L, Huang C, Chen S, Hsiao C, Shan Y, et al. 49P A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer. Ann Oncol. 2021;32:S376\u201381.","journal-title":"Ann Oncol"},{"key":"1623_CR15","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1200\/JCO.2021.39.15_suppl.4080","volume":"39","author":"L Villanueva","year":"2021","unstructured":"Villanueva L, Lwin Z, Chung HCC, Gomez-Roca CA, Longo F, Yanez E, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. J Clin Oncol. 2021;39:4080.","journal-title":"J Clin Oncol"},{"key":"1623_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14:156.","journal-title":"J Hematol Oncol"},{"key":"1623_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28:690\u2013714.","journal-title":"Cancer Cell"},{"key":"1623_CR18","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/cncr.31872","volume":"125","author":"W Sun","year":"2019","unstructured":"Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee JJ, et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer. 2019;125:902\u20139.","journal-title":"Cancer"},{"key":"1623_CR19","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13:1569\u201376.","journal-title":"J Thorac Oncol"},{"key":"1623_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE\u2014version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo Sifiliogr. 2021;112:90\u20132.","journal-title":"Actas Dermo Sifiliogr"},{"key":"1623_CR21","doi-asserted-by":"publisher","first-page":"S570","DOI":"10.1016\/j.annonc.2022.07.093","volume":"33","author":"H Li","year":"2022","unstructured":"Li H. A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers. Ann Oncol. 2022;33:S570.","journal-title":"Ann Oncol"},{"issue":"23","key":"1623_CR22","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335\u201342.","journal-title":"N Engl J Med"},{"issue":"7","key":"1623_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(23)00219-X","volume":"24","author":"MJG Bond","year":"2023","unstructured":"Bond MJG, et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol. 2023;24(7):757\u201371.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1623_CR24","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/sj.bjc.6605908","volume":"103","author":"A Abajo","year":"2010","unstructured":"Abajo A, Rodriguez J, Bitarte N, Zarate R, Boni V, Ponz M, Chopitea A, Bandres E, Garcia-Foncillas J. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. Br J Cancer. 2010;103(10):1529\u201335.","journal-title":"Br J Cancer"},{"issue":"3","key":"1623_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ijc.20100","volume":"110","author":"R Wild","year":"2004","unstructured":"Wild R, Dings RP, Subramanian I, Ramakrishnan S. Carboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer. 2004;110(3):343\u201351.","journal-title":"Int J Cancer"},{"issue":"8","key":"1623_CR26","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMoa1505067","volume":"374","author":"JK Chan","year":"2016","unstructured":"Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O\u2019Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-week paclitaxel and carboplatin for ovarian cancer. New England J Med. 2016;374(8):738\u201348.","journal-title":"New England J Med"},{"issue":"33","key":"1623_CR27","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","volume":"25","author":"RA Burger","year":"2007","unstructured":"Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165\u201371.","journal-title":"J Clin Oncol"},{"key":"1623_CR28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, et al. Nivolumab alone or in combination with oxaliplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4:611\u201321.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1623_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus oxaliplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121\u20138.","journal-title":"Lancet Oncol"},{"key":"1623_CR30","doi-asserted-by":"publisher","first-page":"e001240","DOI":"10.1136\/jitc-2020-001240","volume":"8","author":"X Chen","year":"2020","unstructured":"Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q, et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer. 2020;8:e001240.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1623_CR31","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/s41467-023-38064-w","volume":"14","author":"L Wiedmann","year":"2023","unstructured":"Wiedmann L, De Angelis RF, Vaquero-Siguero N, Donato E, Espinet E, Moll I, Alsina-Sanchis E, Bohnenberger H, Fernandez-Florido E, M\u00fclfarth R, Vacca M, Gerwing J, Conradi LC, Str\u00f6bel P, Trumpp A, Mogler C, Fischer A, Rodriguez-Vita J. HAPLN1 potentiates peritoneal metastasis in pancreatic cancer. Nat Commun. 2023;14(1):2353.","journal-title":"Nat Commun"},{"issue":"1","key":"1623_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.21037\/jgo-21-513","volume":"13","author":"AV Reddy","year":"2022","unstructured":"Reddy AV, Hill CS, Sehgal S, He J, Zheng L, Herman JM, Meyer J, Narang AK. Highneutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer. J Gastrointest Oncol. 2022;13(1):368\u201379.","journal-title":"J Gastrointest Oncol"},{"key":"1623_CR33","doi-asserted-by":"crossref","unstructured":"Rmilah AA, Qrareya MN, Fleming C, Alkurashi AK, Nyberg S, Leise M, Andrews JC. Association of cirrhosis and other patient and procedural characteristics with postembolization syndrome after bland hepatic artery embolization for hepatic malignancy. AJR Am J Roentgenol. 2022;218(6):1030\u201339.","DOI":"10.2214\/AJR.21.26806"},{"issue":"11","key":"1623_CR34","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.hpb.2016.08.006","volume":"18","author":"EW Beal","year":"2016","unstructured":"Beal EW, Wei L, Ethun CG, et al. Elevated NLR in gallbladder cancer and cholangiocarcinoma\u2014making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. HPB (Oxford). 2016;18(11):950\u20137.","journal-title":"HPB (Oxford)"},{"issue":"5","key":"1623_CR35","doi-asserted-by":"publisher","first-page":"e0126496","DOI":"10.1371\/journal.pone.0126496","volume":"10","author":"H Zhang","year":"2015","unstructured":"Zhang H, Zhang L, Zhu K, Shi B, Yin Y, Zhu J, Yue D, Zhang B, Wang C. Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: based on a large cohort study. PLoS ONE. 2015;10(5):e0126496.","journal-title":"PLoS ONE"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01623-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01623-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01623-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:49:39Z","timestamp":1764917379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01623-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01623-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the Board of Directors of Harbin Medical University Cancer Hospital for inclusion in the review. Study participants provided written informed consent for the publication of any potentially identifiable image or data contained herein. The retrospective study was approved by the Ethics Committee of Harbin Medical University Cancer Hospital prior to being performed (approval number is: KY2022-14). The study follows the World Medical Association Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All patients included in this study signed the Second Use Informed Consent for Historical Data\/Biospecimens at Harbin Medical University-afliated Oncology Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"87"}}